DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/v6hqz2/lymphoma_drug) has announced the addition of the "Lymphoma Drug Pipeline Update 2015" report to their offering.
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system.
There are today 263 companies plus partners developing 378 lymphoma drugs in 694 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 140 drugs.
Lymphoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 253 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 241 out of the 245 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 42
- Pre-registration - 2
- Phase III - 30
- Phase II - 141
- Phase I - 175
- Preclinical - 62
- No Data - 12
- Suspended - 3
- Ceased - 140
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/v6hqz2/lymphoma_drug